QMS Medi Approves Scheme of Arrangement and Acquisition of BeamOptics
QMS Medical Allied Services Limited's Board approved a Composite Scheme of Arrangement to merge healthcare businesses of QMS and HCAH into Saarathi Healthcare. It also approved acquiring 100% of BeamOptics Scientific Private Limited. The demerged undertaking of QMS had a turnover of ₹37.17 Crores in FY26. The acquisition of BeamOptics is targeted for completion by November 30, 2027.
The approval of a composite scheme of arrangement involving multiple entities and the acquisition of another company represent substantial corporate actions that could significantly alter the company's structure, operations, and market presence.
The announcement details a significant corporate restructuring through a scheme of arrangement and an acquisition, which are strategic moves aimed at focused growth and expansion into new markets. These actions are generally viewed positively by the market.
QMS Medical Allied Services Limited announced key strategic decisions following a Board Meeting held on September 25, 2026. The Board approved a Composite Scheme of Arrangement involving QMS Medical Allied Services Limited, Health Care at Home India Private Limited (HCAH), and Saarathi Healthcare Private Limited (Resulting Company). This scheme aims to combine the healthcare services businesses of QMS and HCAH into Saarathi, fostering focused growth, operational efficiencies, and synergies. The demerged undertaking of QMS had a turnover of ₹37.17 Crores as of March 31, 2026, representing 24.41% of its total turnover.
Additionally, the company approved the execution of a merger co-operation agreement and a shareholders' agreement among various parties, including the Promoter, Mr. Mahesh Makhija, and entities like Conven Investment Holdings Pte. Limited. QMS also resolved to acquire 100% of the equity shares of BeamOptics Scientific Private Limited, a company involved in designing and manufacturing advanced optics, diagnostics, and analytical instruments for healthcare. The consideration for this acquisition will be determined by an independent valuation report, and a Binding Memorandum of Understanding (MOU) was executed on September 25, 2026. The acquisition of BeamOptics is expected to expand QMS's addressable market in the value-added healthcare business. The indicative completion period for this acquisition is on or before November 30, 2027.
The Board Meeting commenced at 3:15 PM IST and concluded at 3:50 PM IST. The Scheme of Arrangement is subject to approvals from shareholders, creditors, stock exchanges, and the National Company Law Tribunal (NCLT). The Resulting Company intends to seek listing on the National Stock Exchange of India Limited.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under other corporate actions. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.